10% Owner Buys $206K in Passage Bio Following Reverse Merger Announcement
PASG sits 47% above its 52-week low of $3.29.
Summary
A 10% owner purchased $206,101 worth of Passage Bio shares immediately following the announcement of a reverse merger, indicating confidence in the company's new strategic path.
Key Events · Ownership and Investor Activity · PASG
-
Significant Insider Purchase
Nichols Weston, a 10% owner, acquired 50,055 shares of Passage Bio common stock for a total of $206,101 in an open market transaction on June 25, 2026. This represents 1.325% of the company's market capitalization.
-
Post-Merger Confidence
The purchase occurred one day after Passage Bio announced a definitive reverse merger agreement with private company Remix Therapeutics, suggesting the investor sees value in the combined entity.
-
Context of Prior Distress
This investment follows a period of significant operational challenges for Passage Bio, including a going concern warning and a 75% workforce reduction, making the purchase a notable show of support.
Analysis · PASG · Life Sciences
A 10% owner, Nichols Weston (via Lynx1 Capital Management LP), made a significant open market purchase of Passage Bio shares worth $206,101. This transaction occurred on June 25, 2026, just one day after the company announced a definitive reverse merger agreement with Remix Therapeutics. The purchase, representing 1.325% of the company's market capitalization, signals a strong vote of confidence in the company's future direction and the terms of the merger, especially given Passage Bio's recent history of a going concern warning and a major workforce reduction.
At the time of this filing, PASG was trading at $4.85 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $15.6M. The 52-week trading range was $3.29 to $20.00. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.